Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 9;26(1):49.
doi: 10.1007/s11934-025-01279-z.

Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health

Danish Singh  1 , Tivoli Nguyen  2 , Patrick Burnam  2 , Jacob Greenberg  1 , Omer Raheem  3 , Wayne Hellstrom  4
Affiliations
Review

Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health

Danish Singh et al. Curr Urol Rep. .

Abstract

Purpose of review: The aim of this review is to evaluate recent literature surrounding the impact of new medical and surgical therapies for benign prostatic hyperplasia (BPH) on sexual health and function.

Recent findings: Recent randomized controlled trials evaluating patients treated with Optilume, Rezum, Urolift, iTind, and prostatic artery embolism reported minimal associated risks for the development of sexual dysfunction. However, these treatments provide inferior improvement in lower urinary tract symptoms (LUTS) when compared to transurethral resection of the prostate (TURP) and simple prostatectomy. Aquablation demonstrates similar improvement in LUTS while significantly minimizing ejaculatory dysfunction compared to TURP. Management of BPH must include patient counseling on the potential risks of sexual dysfunction associated with both medical and surgical therapies. Future research should be guided towards comparing minimally invasive surgical therapies to one another and collecting long-term data on the durability of these therapies on urinary and sexual function.

Keywords: Ejaculatory disorder; Minimally invasive benign prostatic hyperplasia therapy; Prostate and sexual function; Retrograde ejaculation; Sexual dysfunction; Urination and sexual dysfunction.

PubMed Disclaimer

Conflict of interest statement

Declarations. Disclosures: The authors do not have any relevant disclosures. Human Rights and Animal Rights: This article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of interest: Dr. Omer Raheem is the Section Editor of Current Urology Reports.

Similar articles

See all similar articles

References

    1. Ye Z, Wang J, Xiao Y, et al. Global burden of benign prostatic hyperplasia in males aged 60–90 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urol. 2024;24(1):193. 10.1186/s12894-024-01582-w. - PMC - PubMed
    1. Urologic Diseases in America. 2024 UDA Data Report: Epidemiology of Non-Malignant Urologic Disease in the United States. 2024.
    1. Speakman MJ, Cheng X. Management of the complications of BPH/BOO. Indian J Urol. 2014;30(2):208–13. 10.4103/0970-1591.127856. - PMC - PubMed
    1. Kessler A, Sollie S, Challacombe B, et al. The global prevalence of erectile dysfunction: a review. BJU Int. 2019;124(4):587–99. 10.1111/bju.14813. - PubMed
    1. Carson CC. Erectile dysfunction in the 21st century: Whom we can treat, whom we cannot treat and patient education. Int J Impot Res. 2002;14(Supp 1):S29–34. 10.1038/sj.ijir.3900804. - PubMed

MeSH terms